https://www.selleckchem.com/pr....oducts/5-chloro-2-de
Immunotherapy, targeting programmed death-1 (PD-1) enhances antitumor T-cell activity in patients with malignancies. Blocking PD-1 or its ligand may lead to fulminant colitis as serious adverse event in these patients. Since little is known of the presence and role of PD-1 T cells in colitis of different etiologies, we determined PD-1 T cells in mucosal specimens of patients with inflammatory bowel disease, infectious colitis (InfC), immunotherapy-related colitis (ImC) and healthy controls (HC). Newly diagnosed patients
Like
Comment
Share
